Register for the next Carelon Connects webinar on Wednesday, June 10, at 2pm ET.
As drug prices rise, so does the gross-to-net bubble — increasing rebate dollars without necessarily improving employer affordability. At the same time, policy changes, pricing transparency, and specialty drug expansion are putting new pressure on traditional PBM models.
Join John Watson, PharmD, Chief Growth Officer at CarelonRx, to learn why the market is demanding a different kind of guarantee: one built on aligned incentives, integrated strategy, and accountable total cost of care outcomes.
Register now